Hypoglossal Nerve Stimulation and Cardiovascular Disease Risk in Obstructive Sleep Apnea: A Comprehensive Review

MedXY Editorial Team•Jul 24, 2026•Clinical Updates

Hypoglossal nerve stimulation (HGNS) is an emerging treatment for obstructive sleep apnea (OSA) with promising cardiovascular disease (CVD) risk modification effects over time.
Retrospective cohort data indicate HGNS may reduce incident diabetes and hypertension risk beyond 2 years post-implantation in patients without baseline CVD.
In patients with pre-existing diabetes or hypertension, HGNS is initially associated with higher cardiovascular event diagnosis, which diminishes and reverses after 2 years, suggesting delayed cardiovascular benefits.
Current evidence supports the need for further research to validate findings, dissect subgroup responses, and elucidate underlying biological mechanisms linking HGNS to cardiovascular outcomes.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Hypoglossal nerve stimulation (HGNS) is an emerging treatment for obstructive sleep apnea (OSA) with promising cardiovascular disease (CVD) risk modification effects over time.
Retrospective cohort data indicate HGNS may reduce incident diabetes and hypertension risk beyond 2 years post-implantation in patients without baseline CVD.
In patients with pre-existing diabetes or hypertension, HGNS is initially associated with higher cardiovascular event diagnosis, which diminishes and reverses after 2 years, suggesting delayed cardiovascular benefits.
Current evidence supports the need for further research to validate findings, dissect subgroup responses, and elucidate underlying biological mechanisms linking HGNS to cardiovascular outcomes.